• Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • NP and PA
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
  • Vitiligo
  • Wound Care

Opinion

Video

Oral Systemic Treatment Options for a 28-Year-Old Woman With Moderate Atopic Dermatitis

The panelist discusses how a 28-year-old woman with moderate atopic dermatitis requires personalized, comprehensive management addressing hand involvement, corticosteroid concerns, and potential Janus kinase (JAK) inhibitor therapy, focusing on symptom relief, safety, and patient-specific factors.

Video Player is loading.
Current Time 0:00
Duration 6:32
Loaded: 2.50%
Stream Type LIVE
Remaining Time 6:32
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Video content above is provided by the following:

    • Please provide your initial impressions of this case. Does the involvement of the patient’s hands influence your management plan at all?
    • How would you address the patient’s concerns regarding potential adverse effects of topical corticosteroids?
    • Describe your approach to treatment options for this patient. What patient-specific factors would you take into consideration when deciding on a treatment?
    • In what scenarios would a JAK inhibitor be preferred over another systemic agent?
    • How would decide between a topical or systemic JAK inhibitor for a patient?
    • What can the patient expect in terms of efficacy and safety with upadacitinib? When should she expect initial symptom relief?
    © 2025 MJH Life Sciences

    All rights reserved.